Patents by Inventor Bryan Wayne KING

Bryan Wayne KING has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted pyridines as DNMT1 inhibitors
    Patent number: 11771711
    Abstract: The invention relates to substituted pyridine derivatives that are inhibitors of the activity of DNA methyltransferase 1 (DNMT1). The invention also relates to pharmaceutical compositions comprising such compounds and methods of using such compounds in the treatment of cancer, pre-cancerous syndromes, beta haemoglobinopathy disorders, and other diseases associated with inappropriate DNMT1 activity.
    Type: Grant
    Filed: October 14, 2022
    Date of Patent: October 3, 2023
    Assignee: GlaxoSmith Kline Intellectual Property Development Limited
    Inventors: Andrew B. Benowitz, David T. Fosbenner, Bryan Wayne King, Stuart Paul Romeril
  • SUBSTITUTED PYRIDINES AS DNMT1 INHIBITORS
    Publication number: 20230101987
    Abstract: The invention relates to substituted pyridine derivatives that are inhibitors of the activity of DNA methyltransferase 1 (DNMT1). The invention also relates to pharmaceutical compositions comprising such compounds and methods of using such compounds in the treatment of cancer, pre-cancerous syndromes, beta haemoglobinopathy disorders, and other diseases associated with inappropriate DNMT1 activity.
    Type: Application
    Filed: October 14, 2022
    Publication date: March 30, 2023
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Andrew B. BENOWITZ, David T. Fosbenner, Bryan Wayne King, Stuart Paul Romeril
  • Substituted pyridines as inhibitors of DNMT1
    Patent number: 10975056
    Abstract: The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: April 13, 2021
    Assignees: GlaxoSmithKline Intellectual Property Development Limited, Cancer Research Technology Ltd.
    Inventors: Nicholas David Adams, Andrew B. Benowitz, María Lourdes Rueda Benede, Karen Anderson Evans, David T Fosbenner, Bryan Wayne King, Mei Li, Juan Ignacio Luengo, William Henry Miller, Alexander Joseph Reif, Stuart Paul Romeril, Stanley J. Schmidt, Roger J. Butlin, Kristin M. Goldberg, Allan M. Jordan, Christopher S. Kershaw, Ali Raoof, Bohdan Waszkowycz
  • Heterocyclic amides as kinase inhibitors
    Patent number: 10940154
    Abstract: Disclosed are compounds having the formula: wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A. L, and B are as defined herein, and methods of making and using the same.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: March 9, 2021
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Jae U. Jeong, Deepak Bandyopadhyay, Patrick M. Eidam, Philip Anthony Harris, Jianxing Kang, Bryan Wayne King, Ami Lakdawala Shah, Lara Kathryn Leister, Attiq Rahman, Joshi M. Ramanjulu, Clark A. Sehon, Robert Singhaus, Jr., Daohua Zhang
  • Heterocyclic amides as kinase inhibitors
    Patent number: 10933070
    Abstract: Disclosed are compounds having the formula: wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A. L, and B are as defined herein, and methods of making and using the same.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: March 2, 2021
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Jae U. Jeong, Deepak Bandyopadhyay, Patrick M. Eidam, Philip Anthony Harris, Jianxing Kang, Bryan Wayne King, Ami Lakdawala Shah, Lara Kathryn Leister, Attiq Rahman, Joshi M. Ramanjulu, Clark A. Sehon, Robert Singhaus, Jr., Daohua Zhang
  • HETEROCYCLIC AMIDES AS KINASE INHIBITORS
    Publication number: 20190262356
    Abstract: Disclosed are compounds having the formula: wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A. L, and B are as defined herein, and methods of making and using the same.
    Type: Application
    Filed: May 10, 2019
    Publication date: August 29, 2019
    Inventors: Jae U. JEONG, Deepak Bandyopadhyay, Patrick M. Eidam, Philip Anthony Harris, Jianxing Kang, Bryan Wayne King, Ami Lakdawala Shah, Lara Kathryn Leister, Attiq Rahman, Joshi M. Ramanjulu, Clark A. Sehon, Robert Singhaus, JR., Daohua Zhang
  • HETEROCYCLIC AMIDES AS KINASE INHIBITORS
    Publication number: 20190201413
    Abstract: Disclosed are compounds having the formula: wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A. L, and B are as defined herein, and methods of making and using the same.
    Type: Application
    Filed: March 12, 2019
    Publication date: July 4, 2019
    Inventors: Jae U. JEONG, Deepak Bandyopadhyay, Patrick M. Eidam, Philip Anthony Harris, Jianxing Kang, Bryan Wayne King, Ami Lakdawala Shah, Lara Kathryn Leister, Attiq Rahman, Joshi M. Ramanjulu, Clark A. Sehon, Robert Singhaus, JR., Daohua Zhang
  • SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1
    Publication number: 20190194166
    Abstract: The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Application
    Filed: June 13, 2017
    Publication date: June 27, 2019
    Inventors: Nicholas David ADAMS, Andrew B. BENOWITZ, María Lourdes Rueda BENEDE, Karen Anderson EVANS, David T. FOSBENNER, Bryan Wayne KING, Mei LI, Juan Ignacio LUENGO, William Henry MILLER, Alexander Joseph REIF, Stuart Paul ROMERIL, Stanley J. SCHMIDT, Roger J. BUTLIN, Kristen M. GOLDBERG, Allan M. JORDAN, Christopher S. KERSHAW, Ali RAOOF, Bohdan WASZKOWYCS
  • Heterocyclic amides as kinase inhibitors
    Patent number: 10292987
    Abstract: Disclosed are compounds having the formula: wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A. L, and B are as defined herein, and methods of making and using the same.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: May 21, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Jae U. Jeong, Deepak Bandyopadhyay, Patrick M. Eidam, Philip Anthony Harris, Jianxing Kang, Bryan Wayne King, Ami Lakdawala Shah, Lara Kathryn Leister, Attiq Rahman, Joshi M. Ramanjulu, Clark A. Sehon, Robert Singhaus, Jr., Daohua Zhang
  • Heterocyclic amides as kinase inhibitors
    Patent number: 9556152
    Abstract: Disclosed are compounds having the formula: wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A, L, and B are as defined herein, and methods of making and using the same.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: January 31, 2017
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Philip Anthony Harris, Bryan Wayne King
  • HETEROCYCLIC AMIDES AS KINASE INHIBITORS
    Publication number: 20170008878
    Abstract: Disclosed are compounds having the formula: wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A. L, and B are as defined herein, and methods of making and using the same.
    Type: Application
    Filed: September 21, 2016
    Publication date: January 12, 2017
    Inventors: Deepak BANDYOPADHYAY, Patrick M. EIDAM, Peter J. GOUGH, Philip Anthony HARRIS, Jae U. JEONG, Jianxing KANG, Bryan Wayne KING, Ami LAKDAWALA SHAH, Lara Kathryn LEISTER, Robert W. MARQUIS, JR., Attiq RAHMAN, Joshi M. RAMANJULU, Clark A. SEHON, Robert SINGHAUS, JR., Daohua ZHANG
  • HETEROCYCLIC AMIDES AS KINASE INHIBITORS
    Publication number: 20150353533
    Abstract: Disclosed are compounds having the formula: wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A, L, and B are as defined herein, and methods of making and using the same.
    Type: Application
    Filed: February 14, 2014
    Publication date: December 10, 2015
    Inventors: Deepak BANDYOPADHYAY, Patrick M. EIDAM, Peter J. GOUGH, Philip Anthony HARRIS, Jae U. JEONG, Jianxing KANG, Bryan Wayne KING, Ami LAKDAWALA SHAH, Lara Kathryn LEISTER, Robert W. MARQUIS, JR., Attiq RAHMAN, Joshi M. RAMANJULU, Clark A. SEHON, Robert SINGHAUS, JR., Daohua ZHANG